PortfoliosLab logo
Akebia Therapeutics, Inc. (AKBA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00972D1054

CUSIP

00972D105

IPO Date

Mar 20, 2014

Highlights

Market Cap

$611.28M

EPS (TTM)

-$0.33

Total Revenue (TTM)

$127.57M

Gross Profit (TTM)

$75.60M

EBITDA (TTM)

-$7.61M

Year Range

$0.80 - $2.89

Target Price

$7.30

Short %

6.92%

Short Ratio

2.91

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Akebia Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%200.00%250.00%December2025FebruaryMarchAprilMay
-90.78%
200.81%
AKBA (Akebia Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Akebia Therapeutics, Inc. (AKBA) returned 29.47% year-to-date (YTD) and 75.71% over the past 12 months. Over the past 10 years, AKBA returned -10.64% annually, underperforming the S&P 500 benchmark at 10.31%.


AKBA

YTD

29.47%

1M

38.98%

6M

23.00%

1Y

75.71%

5Y*

-27.23%

10Y*

-10.64%

^GSPC (Benchmark)

YTD

-4.26%

1M

11.24%

6M

-5.02%

1Y

8.55%

5Y*

14.02%

10Y*

10.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of AKBA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202517.89%-17.41%3.78%25.52%2.07%29.47%
202435.48%-5.95%15.82%-31.15%-11.11%-8.93%35.29%12.32%-14.84%25.76%24.10%-7.77%53.23%
20239.19%33.76%-33.50%62.12%14.47%-12.02%82.51%-16.77%-17.99%-22.81%20.45%16.98%114.90%
2022-11.95%8.54%-66.76%-42.16%-10.91%-4.54%10.73%-6.83%-13.20%-19.51%6.29%113.31%-74.47%
202115.71%6.79%-2.17%-5.76%10.03%7.98%-34.83%19.03%-2.04%-0.35%-5.57%-16.61%-19.29%
202014.24%22.85%-14.54%6.86%43.70%16.67%-17.75%-6.80%-75.89%-11.55%49.10%-15.41%-55.70%
2019-0.36%32.12%12.50%-26.25%-26.32%8.76%-13.43%-1.43%-5.08%-4.85%68.63%0.48%14.29%
2018-0.61%-3.25%-33.36%-3.36%6.62%1.63%3.21%-20.29%7.55%-15.18%7.88%-31.56%-62.81%
2017-3.65%-0.10%-8.18%43.26%1.67%7.24%-8.21%26.91%17.50%-7.73%-14.27%-4.43%42.84%
2016-43.27%-0.41%23.42%4.22%-5.11%-16.05%19.65%-9.16%11.32%-16.91%14.49%20.91%-19.43%
2015-11.77%-9.83%19.98%-30.96%2.48%30.92%-8.65%-25.96%38.79%-7.66%20.29%20.41%11.00%
2014-26.73%24.59%-0.29%14.36%-20.33%1.67%-1.69%-41.44%-6.79%-3.64%-56.40%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 83, AKBA is among the top 17% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AKBA is 8383
Overall Rank
The Sharpe Ratio Rank of AKBA is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of AKBA is 8484
Sortino Ratio Rank
The Omega Ratio Rank of AKBA is 8282
Omega Ratio Rank
The Calmar Ratio Rank of AKBA is 8181
Calmar Ratio Rank
The Martin Ratio Rank of AKBA is 8484
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Akebia Therapeutics, Inc. (AKBA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The current Akebia Therapeutics, Inc. Sharpe ratio is 0.99. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Akebia Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00December2025FebruaryMarchAprilMay
0.95
0.44
AKBA (Akebia Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Akebia Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-91.57%
-8.35%
AKBA (Akebia Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Akebia Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Akebia Therapeutics, Inc. was 99.14%, occurring on Nov 29, 2022. The portfolio has not yet recovered.

The current Akebia Therapeutics, Inc. drawdown is 91.57%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.14%Jun 23, 20142126Nov 29, 2022
-36.84%Mar 21, 201416Apr 11, 20145Apr 21, 201421
-21.82%Apr 22, 201420May 19, 201414Jun 9, 201434
-4.91%Jun 10, 20146Jun 17, 20143Jun 20, 20149

Volatility

Volatility Chart

The current Akebia Therapeutics, Inc. volatility is 20.81%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%December2025FebruaryMarchAprilMay
20.81%
11.43%
AKBA (Akebia Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Akebia Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Akebia Therapeutics, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -33.3%.


-0.60-0.40-0.200.000.2020212022202320242025
-0.10
-0.08
Actual
Estimate

Valuation

The Valuation section provides an overview of how Akebia Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for AKBA compared to other companies in the Biotechnology industry. AKBA currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for AKBA relative to other companies in the Biotechnology industry. Currently, AKBA has a P/S ratio of 3.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for AKBA in comparison with other companies in the Biotechnology industry. Currently, AKBA has a P/B value of 4.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items